The NF-κB system of transcription factors plays a crucial role in inflammatory diseases, making it an important drug target. We combined quantitative structure activity relationships for predicting the activity of new compounds and quantitative dynamic models for the NF-κB network with intracellular concentration models. GFA-MLR QSAR analysis was employed to determine the optimal QSAR equation. To validate the predictability of the IKKβ QSAR model for an external set of inhibitors, a set of ordinary differential equations and mass action kinetics were used for modeling the NF-κB dynamic system. The reaction parameters were obtained from previously reported research. In the IKKb QSAR model, good cross-validated q 2 (0.782) and conventional r 2 (0.808) values demonstrated the correlation between the descriptors and each of their activities and reliably predicted the IKKβ activities. Using a developed simulation model of the NF-κB signaling pathway, we demonstrated differences in IκB mRNA expression between normal and different inhibitory states. When the inhibition efficiency increased, inhibitor 1 (PS-1145) led to long-term oscillations. The combined computational modeling and NF-κB dynamic simulations can be used to understand the inhibition mechanisms and thereby result in the design of mechanism-based inhibitors.
Introduction
The NF-κB system of transcription factors plays a crucial role in inflammatory diseases. As a result, the NF-κB signaling pathway has become the most studied and best understood system of transcriptional regulation in molecular biology.
1 When upstream stimuli activate IκB kinase (IKK), IκB is phosphorylated and degraded via the ubiquitinproteosome system. 2 IκB degradation leads to the activation of NF-κB ( Fig. 1) , and NF-κB signal transduction regulates various cellular responses such as inflammation, proliferation, survival, tumor promotion, metastasis, angiogenesis, cell death, and antiproliferative effects. IKKβ (IKK-2) is critical for NF-κB activation, and IKKβ inhibitors are vital for treating treat inflammatory diseases. Research has identified many IKKβ inhibitors. For example, novel quinazoline analogues were identified from the screening of an in-house diversity library. 4 From highthroughput screening of the Bayer compound library, a diarylpyridine derivative was identified as a potent IKKβ inhibitor.
5 β-carbolin analogues ( Fig. 2) inhibit IKKβ with an IC 50 of 150 nM and interfere with NF-κB activation 6, 7 The thiophenecarboxamide derivative SC-514 inhibits the native IKK complex, recombinant human IKK-1/IKK-2 heterodimer, and IKKβ homodimer similarly. IKKβ inhibition by SC-514 is selective, reversible, and competitive with ATP. 8 Recently, among the 60 compounds identified as IKKβ inhibitors by a virtual screening approach, three compounds were shown to potently inhibit the IKKβ enzyme.
9
In this study, we suggest new computational drug discovery approach based on the cheminformatics and systems biology technique. When a compound will be predicted activity against IKKβ enzyme, quantitative concentrations of proteins in NF-κB signaling pathway will be simulated. The NF-κB signaling pathway was modeled and simulated using parameters obtained from a previous study by Hoffmann.
7
Quantitative structure activity relationships were used to predict the IKKβ activity of new compounds, and a quantitative dynamic model was applied to investigate the NF-κB network with intracellular concentration models.
Methods

QSAR Model Construction.
For building a QSAR model, IKKβ inhibitor datasets were taken from BindingDB.
11,12 A subset of 93 compounds from the complete list of 132 inhibitors was utilized as a training set for QSAR modeling. The remaining 39 molecules (ca. 30% of the dataset) comprised an external test set for validating the QSAR model. Descriptors were calculated for each compound by employing the Topomol module in PreADMET software, which was developed by BMDRC. 13 The PreADMET program provides rapid and reliable data of drug-likeness and ADME properties. It can also calculate constitutional, electrostatic, physicochemical, geometric, and topological descriptors that have been developed in response to the need for rapid prediction of drug-likeness and ADME/toxicity data.
The Genetic function approximation-multiple linear regression (GFA-MLR) module in Discovery Studio 2.0 (DS2.0) software 14 was employed to optimize the QSAR regression equation that correlates the biological activities of IKKβ training inhibitors. The activity data of IKKβ [IC 50 (μM)] inhibitors were converted to the logarithmic scale [pIC 50 = −log IC 50 (μM)-6.0] and then used for QSAR analysis. The IKKβ QSAR model was generated with the following optimal GFA parameters: explore linear, quadratic, and spline equations at mating and mutation probabilities of 50%; population size = 500; number of genetic iterations = 30,000; and lack-of-fit (LOF) smoothness parameter = 1.0. The statistical quality of the resulting equations judged by using r 2 was the square of the correlation coefficient and represented the goodness of fit. Internal predictability of the 
. Model Construction and Simulation Protocol. The NF-κB dynamic system model was based on a set of ordinary differential equations and mass action kinetics (Fig.  3) . The reaction parameters were obtained from the work of Hoffmann et al. 10 To investigate the effects of only IKKβ inhibitors, we did not consider the effects of IκBβ and IκBε inhibitors. The dynamic simulation model consisted of 10 ordinary differential equations describing the time evolution of NF-κB, IκBα, and IKKβ concentrations and NF-κB-IκBα, IκBα-IKKβ, and NF-κB-IκBα-IKKβ molecular complexes. The participating molecular species are assumed to translocate between two subcellular compartments: the cytoplasm and the nucleus, thus necessitating considerations about transport rates in addition to binding and reaction rates. The input into the signaling module is represented by the concentration of the active IKK. In the NF-κB dynamic simuation, all four rates are described explicitly. In general, enzymes, substrates and products of individual reactions can be shared among multiple reactions giving rise to more complex differential equations for the corresponding concentrations. Thus, in order to describe changes in the concentration of a reaction component completely, all reactions that this component participates in, plus possible transport, degradation and complex formation rates must be considered. The initial condition was 0.0 µM for free cytoplasmic IκBα and 0.1 µM for both cytoplasmic IKKβ and cytoplasmic NF-κB. All simulations were run using a simple linear ordinary differential equation (ODE) method. Treatment parameters of the linear ODE systems can be found in most standard differential equations textbooks.
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Results and Discussion
IKKβ QSAR Model. We employed GFA-MLR QSAR analysis to determine the optimal QSAR equation. To validate the predictability of the IKKβ QSAR model with an external set of inhibitors, we randomly selected 39 compounds and employed them as the external test set.
Eq. (1) shows the final IKKβ QSAR model. electronegativity is one of the autocorrelation descriptors with electronegativity calculated by the Geary method, which is the summation of the Pauling electronegativity difference between adjunct atoms with Geary correlations.
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No_NsH is the number of single bonds between N atoms and H atoms. SC_06_path is a subgraph count of order 6 (path).
Auto_Geary_06_MPEOE_charge is an autocorrelation descriptor of order 6 MPEOE charges. VS_05 is valence shell count of order 5. were employed for the NF-κB simulation. Inhibitor 1, PS-1145, inhibits IKKβ with an IC 50 of 150 nM. 6 The predicted IC 50 value of the IKKβ QSAR Model was 385 nM. Inhibitor 2, SC-514, also blocks IκBα phosphorylation with an IC 50 of 20 μM against IKKβ. 8 The predicted IC 50 value of the IKKβ QSAR Model was 30.57 μM. We estimated the percent inhibition of IKKβ from the IC 50 values of the two different inhibitors, and PS-1145 was assumed to induce 90% inhibition of IKKβ because it is an extremely strong inhibitor. SC-514 showed mild inhibition, thus we assumed 50% inhibition of IKKβ as the input parameter.
Results of the normal NF-κB simulation showed that a high level of IκBα mRNA expression was achieved by increasing the time scale when compared with other inhibitor simulations. Figure 3 shows the time course of NF-κB in the cytoplasm and IκBα mRNA expression under normal and inhibitory states. The maximum level of IκBα mRNA expression exceeded 0.17 μM without inhibiting IKKβ (Fig. 5(a) ); however, simulation with inhibitors showed that the maximum level of IκBα mRNA expression was slightly reduced (Fig. 5(b) and (c) ). When the inhibition efficiency increased, inhibitor 1, PS-1145, led to long-term oscillations in the output (Fig. 5(c) ).
To facilitate comparisons among different inhibitors of the same pathway, we calculated the area under the curve (AUC) and tabulated the efficiency of inhibitors. For PS-1145, SC-514, and complete inhibition, the differences of AUCs of IκBα mRNA expression were −3.4%, −27.9%, and −57.2%, respectively, based on the simulations reported in Table 1 . The experimental percent inhibition showed similar results, which indicated that PS-1145 elicited 20-50% inhibition of cell line proliferation after 48-hour incubation with PS-1145. 7 For 5400 seconds simulations, we analyzed the relative change of AUC about NF-κB in nucleus and IκBα in cytoplasm. The AUC of NF-κB in nucleus quantitatively decreased −10.4%, −22.8% and −29.1%, and AUC of IκBα in cytoplasm increased 7.4%, 27.9% and 44.1% in Table 2 . These results qualitatively consisted with the results that Multiple Myeloma cells were pre-treated with 0.125-40 μM PS-1145 for 90 min.
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We examined the effect of the IKKβ inhibitor (ML120B) on NF-κB nuclear translocation and DNA binding activity. ML120B, inhibitor 3 in Figure 2 , was employed for the NF-κB simulation for 10 hours. ML120B, inhibits IKKβ with an IC 50 of 60 nM. 17 The predicted IC 50 value of the IKKβ QSAR Model was 534.4 nM. From Dwn D. et al. work, 17 we could assumed the Hillslope of −1.7008 in Eq. (2). The Hillslope characterizes the slope of the curve at its midpoint. This is a typical dose-response curve with a variable slope parameter. Where mM is a fixed inhibitor concentration. IC 50 can be fit to the data using SigmaPlot (Version 11, Systat Software, Inc.)
We applied the Hillsolpe and IC 50 from QSAR predictions to the dose-dependent inhibition of IKKβ inhibitors (ML120B and PHA-408) in Figure 6 (a). ML120B blocked nuclear translocation of NF-κB with an IC 50 of 2.4 μM. 17 We simulated the relative change of % Inhibtion about NF-κB in nucleus in Figure 6 (b). ML120B inhibited nuclear translocation of NF-κB with an IC 50 of 0.95 μM by NF-κB dynamics simulations. PHA-408 inhibits IKKβ with an IC 50 of 40 nM. 18 The predicted IC 50 value of the IKKβ QSAR Model was 6.9 nM. PHA-408 is a selective and potent inhibitor than ML120B. Mbalaviele, B. et al. 19 shows the PHA-408 quantitatively inhibited the NF-κB phosphorylation and DNA binding activity. PHA-408 blocked NF-κB phosphorylation with an IC 50 of 30-40 nM. PHA-408 inhibited PHA-408 shows experimental 68.6-fold and theoretically 87.3-fold stronger activity than ML120B in nuclear translocation of NF-κB. From this study, we proposed that the combined QSAR model for predicting compound activity and dynamics simulation of the NF-κB signaling pathway will provide new insights in inflammation therapy.
Conclusions
Significant progress has been made in recent years regarding the NF-κB signal transduction pathway and the role of NF-κB in inflammation, proliferation, survival, tumor promotion, metastasis, angiogenesis, cell death, and antiproliferative effects. IKKβ is critical for NF-κB activation, thus IKKβ is a potential therapeutic target for NF-κB-related diseases. In this work, we investigated a computational modeling technique (QSAR) and dynamic simulations of the NF-κB signaling pathway in the presence or absence of inhibitors. The IKKb QSAR model was successfully built and was shown to predict the efficacy of inhibitors. Dynamic simulations of the NF-κB signaling pathway could be used to analyze the effects of inhibitors on IκBα mRNA expression and NF-κB translocation. Therefore, we propose that the combined computational modeling and dynamic simulations could help to understand the inhibition mechanisms and thereby result in the design of mechanism-based inhibitors.
